Agilent Technologies stock edged up 1.7% to about US$157.69 after the Q3 print, a calm move for results that told a louder story. The company delivered US$1.88b in revenue with earnings per share of US$1.56 excluding tariff refunds, both ahead of guidance and supported by demand in pharma and applied testing labs.
The central theme is margin strength. Gross and operating margins improved meaningfully, helped by pricing discipline and the Ignite efficiency program. For investors with a longer-term perspective, these margin gains and the raised full year earnings outlook may be more significant than a single positive trading day.
Impressed by Agilent Technologies’ margin strength but want more stocks that pair pricing power with efficiency gains? Take a look at our screener of list of solid balance sheet and fundamentals stocks (50 results).
Prefer clear visuals over scrolling through pages of earnings tables and margin figures for Agilent Technologies? Explore a full visual breakdown of the company, with a focus on its earnings power and profitability trends, in our company report for Agilent Technologies.
Bulls argue Agilent is shifting from a cyclical instrument supplier to a higher quality, margin rich platform built on recurring revenue and Ignite driven efficiencies. Q3 lands close to that script. Core growth of 7.3% with EPS up 14% ex tariff refunds shows revenue quality translating into earnings, not just volume. Gross margin of 54.9% ex refunds is 180 bps higher year on year and operating margin of 27.2% ex refunds is 210 bps higher, which matches the claim that pricing and procurement are doing real work. Recurring orientated CrossLab grew more than 5% and instruments posted high single digit growth with a book to bill above 1 for the tenth straight quarter, which supports the installed base and follow on narrative. Raising full year core growth and EPS guidance, while also lifting the margin expansion target, indicates Ignite is hitting near term milestones.
The bear story around Agilent has focused on tariff pressure, fragile funding and tougher competition eroding margins and capital equipment demand. Q3 does not fully support that view, although it does not remove the risk. Tariff refunds help, so the cleaner test is the ex refund margin. Here, gross margin and operating margin still increase meaningfully year on year, which pushes back on fears that higher input costs would compress profitability. Capital spending sensitivity looks more balanced. Instruments grow at a high single digit rate and a book to bill above 1 for ten straight quarters implies customers are not pulling back replacement cycles yet. Competitive pressure is harder to see in the numbers when pharma grows 12% and PFAS testing grows 20% with GC and LC replacement cycles described as strong. The risk case now rests more on future funding or policy shocks than on current execution.
Access the Agilent Technologies earnings models while the surface looks calm and the stock trades near its latest move. Then see where the consensus breaks on revenue, margin and EPS trajectories in the street’s multi year view through the analyst estimates for Agilent Technologies.
If Agilent Technologies’ margin story and Ignite progress have caught your attention, register for free with Simply Wall St and add it to a Watchlist to track the share price against fair value and watch for a potential entry point. Once you are invested, use the Portfolio Command Center to cut through noise and focus on the updates that matter for your holdings. For a broader view over time, lean on the Community to see how other investors are thinking about opportunities and risks. By spotting hidden catalysts and pressures early, you give yourself a better chance to react quickly and stay ahead of the market.
Fresh ideas can move quickly from quiet to flying, and the most interesting stocks rarely stay under the radar for long. Scan these curated lists before the crowd and act now.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com